In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) -- as well as three neonatal fragment ...

Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...

In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase ...

- Inebilizumab targets CD19+ cells more broadly, now in advanced trials. - Plasma cell-directed agents are emerging to address refractory disease by eliminating antibody-producing cells.

Background Data regarding long-term recovery from autoimmune encephalitis (AE) remain limited. Methods This retrospective ...